A detailed history of Csenge Advisory Group transactions in Clene Inc. stock. As of the latest transaction made, Csenge Advisory Group holds 269,600 shares of CLNN stock, worth $1.53 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
269,600
Previous 116,600 131.22%
Holding current value
$1.53 Million
Previous $50,000 94.0%
% of portfolio
0.01%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 10, 2024

BUY
$0.31 - $0.44 $47,430 - $67,320
153,000 Added 131.22%
269,600 $97,000
Q3 2023

Nov 01, 2023

BUY
$0.46 - $0.87 $53,636 - $101,442
116,600 New
116,600 $58,000

Others Institutions Holding CLNN

About Clene Inc.


  • Ticker CLNN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,502,000
  • Market Cap $360M
  • Description
  • Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...
More about CLNN
Track This Portfolio

Track Csenge Advisory Group Portfolio

Follow Csenge Advisory Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Csenge Advisory Group, based on Form 13F filings with the SEC.

News

Stay updated on Csenge Advisory Group with notifications on news.